Active substances
Clotrimazole + Fluconazole
- Health Canada 2
- UK MHRA 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CANESORAL COMBI 1 DAY | 02490935 | 150 MG / CAP; 2 % / W/W | CREAM; CAPSULE · TOPICAL; ORAL | BAYER INC |
| EXTRA STRENGTH CLOTRIMAZOLE EXTRA FORT -FLUCONAZOLE COMBI | 02517760 | 2 %; 150 MG | CAPSULE; CREAM · TOPICAL; ORAL | TARO PHARMACEUTICALS INC |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| CANESTEN THRUSH DUO ORAL CAPSULE & EXTERNAL CREAM 150MG/2% W/W CAPSULE & CREAM | PL 00010/0652 | BAYER PLC | P |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.